
Novocure’s Optune Pax® Receives CE Mark for Pancreatic Cancer
Novocure Secures CE Mark for Optune Pax in Locally Advanced Pancreatic Cancer Novocure has achieved a significant regulatory milestone after receiving the CE (Conformité Européenne) Mark for Optune Pax®, authorizing…












